Page last updated: 2024-11-04

estriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5756
CHEMBL ID193482
CHEBI ID27974
SCHEMBL ID78033
MeSH IDM0007788

Synonyms (256)

Synonym
BIDD:ER0124
LMST02010003
estra-1,3,5(10)-triene-3,16,17-triol
AB00514045-09
BRD-K17016787-001-03-5
(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16, 17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
gtpl2821
trimesta
estra-1,3,5(10)-triene-3,16,17-triol, (16.alpha.,17.beta.)-
PRESTWICK3_001096
estra-1,3,5(10)-triene-3,16alpha,17beta-triol
estriel
smr000059210
3,16alpha,17beta-trihydroxy-delta(1,3,5)-estratriene
MLS000069812
CHEBI:27974 ,
hsdb 3590
nsc 12169
estra-1,3,5(10)-triene-3,16,17-triol, (16alpha,17beta)-
ccris 284
brn 2508172
oestriol [steroidal oestrogens]
einecs 200-022-2
estriol (jp17/usp)
estriel (tn)
D00185
PRESTWICK2_001096
BPBIO1_001290
oestra-1,5(10)-triene-3,16.alpha.,17.beta.-triol
deuslon a
estra-1,5(10)-trien-3,16.alpha., 17.beta.-triol
theelol
estra-1,5(10)-triene-3,16.alpha., 17.beta.-triol
overstin
3,17.beta.-trihydroxy-.delta.-1,3,5-oestratriene
aacifemine
oestriol
tridestrin
16.alpha.-hydroxyoestradiol
16.alpha.,17.beta.-oestriol
estra-1,5(10)-trien-3,16.alpha.,17.beta.-triol
oestra-1,5(10)-triene-3,16.alpha., 17.beta.-triol
estratriol
oe3 ,
estra-1,5(10)-triene-3,16,17-triol, (16.alpha.,17.beta.)-
wln: l e5 b666ttt&j e1 fq gq oq
1,5(10)-estratriene-3,16.alpha.,17.beta.-triol
orestin
estra-1,5(10)-triene-3,16.alpha.,17.beta.-triol
3,17.beta.-trihydroxyestra-1,3,5(10)-triene
ovestin
a 13610
16.alpha.-hydroxy-17.beta.-estradiol
(16.alpha.,3,5(10)-triene-3,16,17-triol
destriol
ortho-gynest
16.alpha.,17.beta.-estriol
1,5(10)-estratriene-3,16.alpha., 17.beta.-triol
ovestrion
thulol
nsc12169 ,
1,5-estratriene-3.beta.,16-.alpha.,17-.beta.-triol
16.alpha.-estriol
3,17.beta.-trihydroxy-1,3,5(10)-estratriene
3,17.beta.-trihydroxy-.delta.-1,3,5-estratriene
16.alpha.-hydroxyestradiol
trihydroxyestrin
nsc-12169
oestratriol
1,5-oestratriene-3-.beta.,16.alpha.,17.beta.-triol
cas-50-27-1
BSPBIO_001172
SMP1_000122
NCGC00179277-01
(13s,16r,17r)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthrene-3,16,17-triol
hormonin
triovex
3,16-alpha,17-beta-trihydroxy-delta-1,3,5-oestratriene
16alpha-hydroxyoestradiol
orgastyptin
trihydroxyoestrin
oestra-1,3,5(10)-triene-3,16alpha,17beta-triol
16alpha-hydroxyestradiol
3,16-alpha,17-beta-trihydroxyoestra-1,3,5(10)-triene
3,16-alpha,17-beta-estriol
1,3,5-oestratriene-3beta,16alpha,17beta-triol
synapause
oestriolum
16-alpha,17-beta-estriol
3,16-alpha,17-beta-trihydroxy-delta-1,3,5-estratriene
klimoral
gynaesan
holin
16alpha,17beta-oestriol
estriol, unconjugated
3,16-alpha,17-beta-trihydroxyestra-1,3,5(10)-triene
3,16-alpha,17-beta-oestriol
triodurin
oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol
estra-1,3,5(10)-trien-3,16alpha,17beta-triol
estriolo [italian]
hormomed
16alpha-hydroxy-17beta-estradiol
stiptanon
deuslon-a
16alpha,17beta-estriol
16-alpha-hydroxyoestradiol
3,16alpha,17beta-estriol
estra-1(10),2,4-triene-3,16,17-triol, (16alpha,17beta)-
(16alpha,17beta)-oestra-1,3,5(10)-triene-3,16,17-triol
16-alpha,17-beta-oestriol
3,16alpha,17beta-trihydroxy-1,3,5(10)-estratriene
1,3,5-estratriene-3beta,16alpha,17beta-triol
3,16alpha,17beta-trihydroxy-delta-1,3,5-oestratriene
16-alpha-hydroxyestradiol
hemostyptanon
(16alpha,17beta)-estra-1,3,5(10)-triene-3,16,17-triol
AB00514045
C05141
estriol ,
1,3,5(10)-estratriene-3,16-alpha,17beta-triol
50-27-1
1,3,5(10)-estratriene-3,16,17-triol
estriol, >=97%
estriol, meets usp testing specifications
NCGC00166111-01
DB04573
PRESTWICK1_001096
SPBIO_003056
PRESTWICK0_001096
16alpha,17beta estriol
16-hydroxyestradiol
6EC6F23B-A991-4606-8BC7-146D915DAB31
HMS2090E20
colpogyn
CHEMBL193482
incurin
e0218 ,
HMS1571K14
NCGC00166111-02
HMS2098K14
dtxsid9022366 ,
NCGC00255193-01
dtxcid002366
tox21_301604
tox21_112320
chlorapatite
1306-04-3
BCP9000661
HMS2234A18
1,3,5(10)-estratriene-3,16alpha,17beta-triol
bdbm50410506
BCP0726000219
estriol [usp:inn:ban:jan]
estriolo
unii-fb33469r8e
4-06-00-07550 (beilstein handbook reference)
fb33469r8e ,
estriol [hsdb]
estriol [ep monograph]
estriol [green book]
estriol [ema epar veterinary]
estriol [jan]
1,3,5-estratriene-3b,16a,17b-triol
(16a,17b)-estra-1,3,5(10)-triene-3,16,17-triol
estriol [usp monograph]
estriol [mi]
estriol [usp-rs]
estriol [mart.]
estriol [who-dd]
13.beta.-methyl-1,3,5(10)-gonatriene-3,16.alpha.,17.beta.-triol
EPITOPE ID:140131
AKOS015894926
S2466
AB00514045-08
CCG-221096
HY-B0412
SCHEMBL78033
tox21_112320_1
NCGC00274080-01
Q-201072
estra-1,3,5(10)-triene-3,16,17-triol, (16a,17b)-
1,3,5-oestratriene-3-.beta.,16.alpha.,17.beta.-triol
klimax e
1,3,5(10)-estratriene-3,16.alpha.,17.beta.-triol
3,16-.alpha.,17-.beta.-oestriol
gynasan
estra-1,3,5(10)-triene-3,16-.alpha., l7-.beta.-triol
estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol
(16.alpha.,17.beta.)-oestra-1,3,5(10)-triene-3,16,17-triol
1,3,5(10)-estratrien-3,16.alpha.,17.beta.-triol
3,16.alpha.,17.beta.-trihydroxyestra-1,3,5(10)-triene
1,3,5-estratriene-3.beta.,16-.alpha.,17-.beta.-triol
ovo-vinces
ovesterin
3,16.alpha.,17.beta.-trihydroxy-1,3,5(10)-estratriene
3,16-.alpha.,17-.beta.-trihydroxyoestra-1,3,5(10)-triene
3,16.alpha.,17.beta.-estriol
oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol
estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol
3,16.alpha.,17.beta.-trihydroxy-.delta.-1,3,5-estratriene
(16.alpha.,17.beta.)-estra-1,3,5(10)-triene-3,16,17-triol
3,16.alpha.,17.beta.-trihydroxy-.delta.-1,3,5-oestratriene
FD12050
AB00514045_10
estriol, purum, >=97.0% (hplc)
SR-01000721851-3
sr-01000721851
SR-01000721851-4
estriol, 98%
estriol, vetranal(tm), analytical standard
estriol, united states pharmacopeia (usp) reference standard
estriol, european pharmacopoeia (ep) reference standard
estriol 100 microg/ml in acetonitrile
estriol 1.0 mg/ml in methanol
HMS3715K14
estra-1,3,5(10)-triene-3,16a,17b-triol
3,16a,17b-trihydroxyestra-1,3,5(10)-triene
3,16a,17b-estriol
16a-estriol
13b-methyl-1,3,5(10)-gonatriene-3,16a,17b-triol
3,16alpha,17beta-trihydroxyestra-1,3,5(10)-triene
16a,17b-estriol
holin v
ovestinon
estriol for system suitability, european pharmacopoeia (ep) reference standard
(9beta,13alpha,16beta,17beta)-estra-1(10),2,4-triene-3,16,17-triol
Q409721
(8r,13s,16r,17r)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthrene-3,16,17-triol
(1s,10r,11s,13r,14r,15s)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,13,14-triol
AS-13735
BCP23357
BRD-K17016787-001-16-7
HMS3884P19
(s)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acidt-butyl ester
oestriol.
EN300-7390799
(1r,2r,3as,3br,9bs,11as)-11a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-1,2,7-triol
HY-B0412R
CS-0694816
estriol (standard)
13beta-methyl-1,3,5(10)-gonatriene-3,16alpha,17beta-triol
estro-life
estriol (usp monograph)
estriol (mart.)
ostriol
estriol (ema epar veterinary)
advanced formula estro-life
estriol (usp:inn:ban:jan)
3,16alpah,17beta-trihydroxyestra-1,3,5(10)-triene
estriol 5.0 cream
trophicreme
estriol (usp-rs)
gynsan
estriol (ep monograph)
16alpha-estriol

Research Excerpts

Overview

Estriol (E3) is an endogenous estrogen in females with broad biological activity within diverse tissue types. Estriol is a weak estrogen that is not Food and Drug Administration approved for use as a prescription drug in the United States.

ExcerptReferenceRelevance
"Estriol (E3) is an endogenous estrogen in females with broad biological activity within diverse tissue types. "( Estriol Reduces Pulmonary Immune Cell Recruitment and Inflammation to Protect Female Mice From Severe Influenza.
Attreed, SE; Klein, SL; Ursin, RL; Vermillion, MS, 2018
)
3.37
"Estriol is a weak estrogen that is not Food and Drug Administration approved for use as a prescription drug in the United States; thus, clinical trials are necessary to demonstrate the efficacy and safety profile for estriol."( Bioidentical hormone therapy: a panacea that lacks supportive evidence.
Boothby, LA; Doering, PL, 2008
)
1.07
"Estriol is an estrogen with considerably weaker stimulatory effects on endometrial proliferation than estradiol. "( Expression of estrogen and progesterone receptor genes in endometrium, myometrium and vagina of postmenopausal women treated with estriol.
Bryś, M; Dobrowolski, Z; Krajewska, W; Masłowska, I; Romanowicz-Makowska, H; Szyłło, K, 2009
)
2
"Estriol is an antioxidant, increases the lag-phase of LDL-oxidation in vitro, and its serum concentration raises enormous during late pregnancy."( Placental defence is considered sufficient to control lipid peroxidation in pregnancy.
Beckmann, MW; Binder, H; Dittrich, R; Hoffmann, I; Koebnick, C; Mueller, A; Schild, RL, 2005
)
1.05
"Estriol is an increasingly popular alternative hormone therapy used for menopausal symptoms."( Hormone replacement therapy in menopausal women: Past problems and future possibilities.
Curcio, J; Kim, LS; Riedlinger, J; Schmidt, JW; Wollner, D, 2006
)
1.06
"Estriol is a short acting estrogen, and as such, displays both agonistic and antagonistic properties, when it is injected in saline solution. "( The agonistic and antagonistic actions of estriol.
Clark, JH; Markaverich, BM, 1984
)
1.97
"Estriol is a poor stimulator of uterine growth and plasminogen activator activity in vivo."( Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo.
Katzenellenbogen, BS, 1984
)
1.26
"Estriol is a weak estrogen with a claimed specific action on the epithelium in cervix uteri and vagina and with no or limited ability to induce endometrial proliferation. "( Endometrial effect of oral estriol treatment in postmenopausal women.
Englund, DE; Johansson, ED, 1980
)
2
"Estriol is a weak estrogen with a claimed specific action on the epithelium in cervix uteri and vagina and with limited or no ability to induce endometrial proliferation. "( Endometrial effect of oral estriol treatment in postmenopausal women.
Englund, DE; Johansson, ED, 1980
)
2
"Oestriol is a weak, naturally occurring oestrogen that may be beneficial to the urogenital tissues without stimulating the endometrium."( Oestriol in the treatment of postmenopausal urgency: a multicentre study.
Barlebo, H; Barnick, C; Cardozo, L; Kerr-Wilson, R; Rekers, H; Schussler, B; Shepherd, A; Tapp, A; van Geelan, J; Walter, S, 1993
)
1.82
"Estriol acts as a weak estrogen when administered in a single dose into immature or ovariectomized laboratory animals, but produces full estrogenic responses upon chronic administration. "( Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol.
Castaño, E; Melamed, M; Notides, AC; Sasson, S, 1997
)
1.97
"Estriol is a safe and effective alternative for relieving climacteric symptoms in postmenopausal Japanese women."( Efficacy and safety of oral estriol for managing postmenopausal symptoms.
Kanasaki, H; Kurioka, H; Manabe, A; Miyazaki, K; Okada, M; Takahashi, K, 2000
)
2.04
"Estriol is an estrogen with considerably weaker stimulatory effects on endometrial proliferation than estradiol. "( Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women.
Okamura, H; Yoshimura, T, 2001
)
2.1
"Estriol is a stronger estrogen than estradiol-17beta for the estrogen-induced uterine eosinophilia and the 6 h increase in the uterine wet weight."( Correlation of estrogen-induced uterine eosinophilia with other parameters of estrogen stimulation, produced with estradiol-17beta and estriol.
Galand, P; Tchernitchin, A; Tchernitchin, X, 1975
)
1.18

Effects

Estriol has an apparent selective effect on vaginotropic events. The estriol level has a limited value in the diagnosis of RIUG.

Nilestriol (NIL) has been applied to treat menopausal dysfunctions, yet its mechanism has remained unknown. The estriol level has a limited value in the diagnosis of RIUG. Estriol has been found to provide some of the protection without the risks associated with stronger estrogens.

ExcerptReferenceRelevance
"The estriol level has a limited value in the diagnosis of RIUG."( [Value and limits of estrioluria in cases of retarded fetal growth].
Benbassa, A; Chambaz, P; Malinas, Y; Mas, M; Racinet, C; Villemin, D, 1973
)
1.05
"Estriol has an apparent selective effect on vaginotropic events."( The agonistic and antagonistic effects of short acting estrogens: a review.
Clark, JH; Markaverich, BM, 1983
)
0.89
"Nilestriol (NIL) has been applied to treat menopausal dysfunctions, yet its mechanism has remained unknown. "( (1)H NMR metabolic profiling analysis offers evaluation of Nilestriol treatment in ovariectomised rats.
Dong, JX; Huang, RQ; Liu, YR; Xiao, BK; Yang, JY, 2014
)
1.26
"Estriol has some unique physiological effects, which differentiate it from estradiol, estrone, and CEE."( The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
Holtorf, K, 2009
)
1.31
"Estriol has been showed to prevent bone loss in osteoporotic rats and postmenopausal women, but the mechanisms remain unclear. "( Effects of estriol on the proliferation and differentiation of human osteoblastic MG-63 cells.
Liao, EY; Luo, XH, 2003
)
2.15
"The estriol level has a limited value in the diagnosis of RIUG."( [Value and limits of estrioluria in cases of retarded fetal growth].
Benbassa, A; Chambaz, P; Malinas, Y; Mas, M; Racinet, C; Villemin, D, 1973
)
1.05
"Estriol has been reported to act selectively on the vagina and cervix without causing endometrial proliferations. "( Comparative effect of estriol and equine conjugated estrogens on the uterus and the vagina.
Hahn, DW; McGuire, JL; Phillips, A, 1984
)
2.02
"Estriol has an apparent selective effect on vaginotropic events."( The agonistic and antagonistic effects of short acting estrogens: a review.
Clark, JH; Markaverich, BM, 1983
)
0.89
"Estriol has been found to provide some of the protection without the risks associated with stronger estrogens."( Estriol: safety and efficacy.
Head, KA, 1998
)
2.46
"Estriol has been described to be a weak and short-acting estrogen without an increased risk of endometrial proliferation and hyperplasia."( Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Ando, K; Kikuchi, A; Matsumi, H; Momoeda, M; Nakayama, H; Osuga, Y; Sagara, Y; Taketani, Y; Wang, Y; Watanabe, M; Yano, T, 1999
)
2.47
"Estriol, which has little effect on the endometrium, has the potential to be highly useful for the treatment of atrophic vaginitis."( Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women.
Okamura, H; Yoshimura, T, 2001
)
2.1
"Estriol (E3) has little effect on the female genitals. "( Estriol retards and stabilizes atherosclerosis through an NO-mediated system.
Endo, H; Hayashi, T; Iguchi, A; Kano, H; Matusi-Hirai, H; Sumi, D; Tsunekawa, T, 2002
)
3.2
"Estriol has no effect."( Diethylstilbestrol-elicited accumulation of cyclic AMP in incubated rat hypothalamus.
Daly, JW; Skolnick, P; Weissman, BA, 1975
)
0.98

Actions

Estriol is able to produce the same endometrial effect as estradiol. Estriol was lower in sPE, but not in mPE.

ExcerptReferenceRelevance
"Estriol was lower in sPE, but not in mPE."( Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction.
Jobe, SO; Magness, RR; Tyler, CT, 2013
)
1.11
"Thus estriol is able to produce the same endometrial effect as estradiol."( The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose.
Punnonen, R; Söderström, KO, 1983
)
1.05

Treatment

Estriol treatment initiated after disease onset decreased cerebral cortex atrophy. Estriol (0.6nM) treatment also influenced the DCN-2 induced inhibition of nitric oxide (NO) synthesis.

ExcerptReferenceRelevance
"Estriol treatment initiated after disease onset decreased cerebral cortex atrophy."( Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.
Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023
)
1.87
"Estriol (0.6nM) treatment also influenced the DCN-2 induced inhibition of nitric oxide (NO) synthesis from 0nmol NO/ml to 0.56nmol/ml."( Estriol Inhibits Dermcidin Isoform-2 Induced Inflammatory Cytokine Expression Via Nitric Oxide Synthesis in Human Neutrophil.
De, SK; Guha, S; Jana, P; Khan, GA; Khan, MM; Maiti, S; Sinha, AK, 2018
)
2.64
"Estriol treatment completely inhibited 17β-estradiol-induced p-src activation."( Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.
Emons, G; Girgert, R; Gründker, C, 2014
)
1.43
"Estriol treatment is anti-inflammatory and neuroprotective in preclinical studies."( Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Arnold, DL; Bardens, J; Bernard, JT; Corboy, JR; Cross, AH; Dhib-Jalbut, S; Elashoff, R; Ford, CC; Frohman, EM; Giesser, B; Itoh, N; Jacobs, D; Kasper, LH; Kurth, F; Lynch, S; MacKenzie-Graham, AJ; Nakamura, K; Parry, G; Racke, MK; Reder, AT; Rose, J; Sicotte, NL; Tseng, CH; Voskuhl, RR; Wang, H; Wingerchuk, DM; Wu, TC, 2016
)
2.6
"Estriol treatment of mice with EAE reduced MMP-9 in supernatants from autoantigen-stimulated splenocytes, coinciding with decreased CNS infiltration by T cells and monocytes."( Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha).
Du, S; Gold, SM; Morales, LB; Sasidhar, MV; Sicotte, NL; Tiwari-Woodruff, SK; Voskuhl, RR, 2009
)
1.07
"Estriol treatment produced a 2.5-fold increase in visfatin gene expression."( Estrogens induce visfatin expression in 3T3-L1 cells.
Seidel, ER; Zhou, J, 2010
)
1.08
"Estriol treatment prevented decreases in excitatory synaptic transmission and lessened the effect of EAE on PPF."( Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Avedisian, AA; Dervin, SM; O'Dell, TJ; Voskuhl, RR; Ziehn, MO, 2012
)
2.54
"Estriol treatment resulted in a rise of vaginal health index (VHI), appearance of lactobacteria in the vaginal smear, lowering of atrophic vaginitis detection rate."( [Methods of diagnosis and treatment of asymptomatic bacteriuria in postmenopausal women suffering from type 2 diabetes mellitus].
Berketova, TIu; Kasian, GR; Rubanov, VA; Sarkisian, AZ,
)
0.85
"Estriol treatment in vivo enhances LPS-induced NO production in Kupffer cells."( Estriol enhances lipopolysaccharide-induced increases in nitric oxide production by Kupffer cells via mechanisms dependent on endotoxin.
Enomoto, N; Hirose, M; Ikejima, K; Kitamura, T; Sato, N; Takei, Y, 2002
)
3.2
"When estriol treatment was stopped, enhancing lesions increased to pretreatment levels."( Treatment of multiple sclerosis with the pregnancy hormone estriol.
Bouvier, S; Klutch, R; Liva, SM; Odesa, S; Pfeiffer, P; Sicotte, NL; Voskuhl, RR; Wu, TC, 2002
)
1.01
"Oestriol treatment had no effect on dopaminergic markers in MPTP mice whereas oestrone prevented striatal DAT loss and the decrease of VMAT2 mRNA in the substantia nigra."( Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Di Paolo, T; Jourdain, S; Morin, N; Morissette, M, 2005
)
0.95
"Estriol treatment also resulted in cranially hypertrophied oviducts at all incubation temperatures in a dose-dependent manner, whereas animals treated with estradiol-17 beta and estrone had normal oviducts."( The relative effectiveness of estrone, estradiol-17 beta, and estriol in sex reversal in the red-eared slider (Trachemys scripta), a turtle with temperature-dependent sex determination.
Cantú, AR; Crews, D; Rhen, T; Vohra, R, 1996
)
1.26
"Estriol treated mice also exhibited a rapid elevation in serum IL-6 levels following LPS challenge with the peak increase occurring 1 hr post LPS."( Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxemia.
Ahmari, SE; Bryan-Poole, N; Evans, GF; Glasebrook, AL; Short, L; Zuckerman, SH, 1996
)
2.46
"Estriol treatment reduced the severity of EAE significantly compared with placebo treatment whereas progesterone treatment had no effect. "( Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis.
Dalal, MA; Kim, S; Liva, SM; Verity, MA; Voskuhl, RR, 1999
)
3.19
"Estriol treatment significantly lowered serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations but did not affect any of the other parameters (lipids, bone, liver and blood pressure) during the study period."( Efficacy and safety of oral estriol for managing postmenopausal symptoms.
Kanasaki, H; Kurioka, H; Manabe, A; Miyazaki, K; Okada, M; Takahashi, K, 2000
)
1.32
"The estriol treatment per vaginam is not so effective on the result of Burch culposuspension in postmenopausal women with IUS."( [Effect of estriol treatment per vaginam before Burch culposuspension].
Acunzo, G; Di Spiezio Sardo, A; Mandato, V; Napolitano, V; Nappi, C; Palomba, S; Ruoto, M; Sammartino, A; Vassallo, M; Votino, C, 2001
)
1.26
"Oestriol succinate treatment lowered the ratio E1/(E2 + E3), which was rather similar to the one during normal menstrual cycle."( Serum oestriol, oestrone and oestradiol concentrations during oral oestriol succinate treatment in ovariectomized women.
Grönroos, M; Kaihola, HL; Punnonen, R; Rauramo, L, 1978
)
1.33

Toxicity

Estriol can be a safe and effective alternative in the relief of climacteric symptoms for postmenopausal women, but it cannot prevent the bone loss.

ExcerptReferenceRelevance
" It can be concluded that single daily treatment with intravaginal estriol in the recommended doses in postmenopausal women is safe and without an increased risk of endometrial proliferation or hyperplasia."( Review of the endometrial safety during intravaginal treatment with estriol.
Geurts, TB; Vooijs, GP, 1995
)
0.76
"Estriol can be a safe and effective alternative in the relief of climacteric symptoms for postmenopausal women, but it cannot prevent the bone loss."( Efficacy and safety of estriol replacement therapy for climacteric women.
Chang, SP; Ng, HT; Tsan, SH; Yang, TS, 1995
)
2.04
"Estriol is a safe and effective alternative for relieving climacteric symptoms in postmenopausal Japanese women."( Efficacy and safety of oral estriol for managing postmenopausal symptoms.
Kanasaki, H; Kurioka, H; Manabe, A; Miyazaki, K; Okada, M; Takahashi, K, 2000
)
2.04
" Therefore, oestriol appeared to be safe and effective in relieving symptoms of menopausal women."( Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause.
Kanasaki, H; Kurioka, H; Manabe, A; Miyazaki, K; Okada, M; Ozaki, T; Takahashi, K, 2000
)
0.98
" The incidences of adverse events were similar in all groups."( Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
Gräser, T; Koytchev, R; Müller, A; Oettel, M, 2000
)
0.31
"Intravaginal administration of a combination estriol and progesterone agent to women with atrophic vaginitis may represent a safe and effective alternative to systemic hormone replacement, although this study was not adequate to provide proof of efficacy given that it was uncontrolled."( Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Balk, JL; Carter, G; Chollet, JA; Mermelstein, F; Meyn, LA,
)
0.68
" Safety assessments included vital signs, laboratory examinations of the vaginal microecosystem, vaginal pH value, vaginal B ultrasound, and incidence of adverse events."( Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial.
Chen, J; Geng, L; Giordan, N; Li, H; Liao, Q; Song, X, 2013
)
0.39
"03 mg E3 and Lactobacillus acidophilus vaginal tablets application in postmenopausal BC patients during AI treatment suffering from vaginal atrophy lead to small and transient increases in serum E3, but not E1 or E2, and therefore can be considered as safe and efficacious for treatment of atrophic vaginitis in BC patients taking NSAIs."( Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Moegele, M; Neven, P; Ortmann, O; Prasauskas, V, 2014
)
0.76
" These studies confirmed the efficacy of local estrogens to treat symptoms of vulvovaginal atrophy with few adverse effects reported."( The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.
Avellaneda, AC; Osorio, AM; Pinzón, CE; Restrepo, OI; Rueda, C, 2017
)
0.75
"The available evidence (of low and moderate quality) shows that, when administered vaginally, estriol preparations appear to be safe for women who have risk factors related to systemic estrogen therapy."( The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.
Avellaneda, AC; Osorio, AM; Pinzón, CE; Restrepo, OI; Rueda, C, 2017
)
0.97
" This study shows that PPARG in placenta may mediate the adverse effects of phthalates on pregnancy in human."( Peroxisome proliferator activated receptor gamma in human placenta may mediate the adverse effects of phthalates exposure in pregnancy.
Chen, JA; Garcia, JM; Huang, Y; Lin, H; Rong, H; Shu, W; Tan, Y; Wang, Y; Zeng, H; Zhang, L, 2018
)
0.48
" Vaginal estrogen products seem to be safe with few adverse effects, although there is a lack of long-term controlled clinical trial safety data."( A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.
Biehl, C; Mirkin, S; Plotsker, O, 2019
)
0.51
" Vaginal pH measurement, subjective symptoms, and objective signs assessment of VVA, endometrial thickness and adverse events (AE) were recorded."( Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Amar, ID; Cipolla, C; Ingravalle, F; Lanzone, A; Ricciardi, W; Scambia, G; Tagliaferri, V; Villa, P, 2020
)
0.88
" Vaginal estrogens effectively improve these symptoms, although their safe use in breast cancer survivors remains unclear."( A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aroma
Bermejo-De Las Heras, B; Gil-Gil, M; Hirschberg, AL; Nieto-Magro, C; Sánchez-Rovira, P, 2020
)
0.76
" Adverse events and discomfort encountered during the procedure were also assessed."( Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
Alvisi, S; Baldassarre, M; Lami, A; Lenzi, J; Mancini, I; Meriggiola, MC; Seracchioli, R, 2022
)
0.95

Pharmacokinetics

ExcerptReferenceRelevance
" From this the basic pharmacokinetic parameters were calculated and experimentally confirmed by multiple-dosing data."( [Pharmacokinetics of 14 beta-, 15 beta-methylenestratriene STS 593 after one-time and multiple administrations to beagles].
Hillesheim, HG; Schumann, W, 1987
)
0.27
" After micronized 17 beta-oestradiol however, there was a 2-3-fold increase in the ratio at Cmax and slower elimination of 17 beta-oestradiol from plasma, which may be due to the fact that high serum oestrone levels may serve as a reservoir, since both a metabolite and also a precursor of 17 beta-oestradiol."( Pharmacokinetic evaluation of oral 17 beta-oestradiol and two different fat soluble analogues in ovariectomized women.
Cullberg, G; Hedner, T; Schubert, W, 1993
)
0.29
"It was the aim of the study to compare the pharmacokinetic properties of the two new estrogens, ZK 136295 and ZK 115194, with those of ethinylestradiol (EE2) after single intravenous (60 micrograms) and oral (120 and 240 micrograms) administration in 54 postmenopausal women."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
"7 hours); and EE2 had a mean terminal half-life of 26."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" The pharmacokinetic profile of the serum concentrations of estradiol was measured on day 1, 21 and 28 each immediately before and 1, 2, 4, 6, 8, and 10 hours after intake of a tablet, and the AUC (area under the curve) was calculated."( [Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol].
Fink, T; Kuhl, H; Lang, E; Leukel, P; Rohr, UD; Wiegratz, I, 2001
)
0.31
" Pharmacokinetic parameters, AUC, C(max) and t(max), were determined from the plasma concentration-time curves using non-compartmental methods."( Pharmacokinetics of oestriol after repeated oral administration to dogs.
Coert, A; Hoeijmakers, M; Horspool, L; Janszen, B, 2003
)
0.64
" In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats."( Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004
)
0.32
"Bioidentical compounded hormone therapy is popular among patients, but providers do not have pharmacokinetic information or dosing guidelines for these preparations."( Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial.
Bahn, RS; Rhodes, DJ; Schroeder, DR; Shuster, LT; Singh, RJ; Sood, R; Wahner-Roedler, D; Warndahl, RA, 2013
)
0.39
"This pharmacokinetic trial showed that the currently used doses of compounded hormones yield lower levels of estrogen compared to the standard-dose estradiol patch."( Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial.
Bahn, RS; Rhodes, DJ; Schroeder, DR; Shuster, LT; Singh, RJ; Sood, R; Wahner-Roedler, D; Warndahl, RA, 2013
)
0.39
"Thirty-six women were included in the pharmacokinetic analysis."( Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women.
Delgado, JL; Estevez, J; Loprete, L; Moscoso Del Prado, J; Nieto Magro, C; Radicioni, M, 2016
)
0.65
" In each treatment period, an endometrial biopsy for histological evaluation was performed on Day 23 and pharmacokinetic parameters were determined after the first progesterone dose on Day 15 and after the last dose on Day 24."( Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo.
Duijkers, IJM; Hrafnsdottir, S; Klingmann, I; Klipping, C; Magnusdottir, TB; Prinz, R; Wargenau, M, 2018
)
0.48
" Pharmacokinetic parameters after repeated dosing of vaginal pessaries showed a dose-dependent, but not dose-proportional, increase of plasma progesterone levels."( Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo.
Duijkers, IJM; Hrafnsdottir, S; Klingmann, I; Klipping, C; Magnusdottir, TB; Prinz, R; Wargenau, M, 2018
)
0.48
" Oestradiol (E2) and progesterone (PG) serum concentrations, and bleeding patern were determined as pharmacodynamic parameters."( Single-dose pharmacokinetics and pharmacodynamics assessment of oestriol and trimegestone containing vaginal rings in healthy women with childbearing potential.
de Jesus Antunes, N; De Nucci, G; de Oliveira Filho, RV; de Oliveira Ilha, J; Moreno, RA; Nahoum, AF; Warnke, A; Wedemeyer, RS, 2021
)
0.86

Compound-Compound Interactions

Restoration of the vaginal flora can be significantly enhanced by the administration of live lactobacilli in combination with low dose oestriol.

ExcerptReferenceRelevance
"25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo."( Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
Christensen, MS; Christiansen, C; Hagen, C; Rødbro, P; Transbøl, I, 1981
)
0.26
"To evaluate the effectiveness of live lactobacilli in combination with low dose oestriol for restoration of the vaginal flora after anti-infective treatment."( The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections.
Grob, P; Kaiser, R; Ozkinay, E; Terek, MC; Tuncay, G; Yayci, M, 2005
)
0.79
"Three hundred and sixty women with the complaints of vaginal infections (bacterial vaginosis, candidiasis, trichomoniasis or fluor vaginalis) were randomly assigned two to seven days after the end of the anti-infective therapy, to therapy with live lactobacilli in combination with low dose oestriol (study group, n= 240) or placebo (n= 120)."( The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections.
Grob, P; Kaiser, R; Ozkinay, E; Terek, MC; Tuncay, G; Yayci, M, 2005
)
0.74
"Restoration of the vaginal flora can be significantly enhanced by the administration of live lactobacilli in combination with low dose oestriol."( The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections.
Grob, P; Kaiser, R; Ozkinay, E; Terek, MC; Tuncay, G; Yayci, M, 2005
)
0.77
"To compare the urodynamic and morphologic effects of the administration of estriol alone and in combination with phenylpropanolamine on the lower portion of the urogenital tract in female dogs."( Urodynamic and morphologic changes in the lower portion of the urogenital tract after administration of estriol alone and in combination with phenylpropanolamine in sexually intact and spayed female dogs.
Balligand, MH; Farnir, F; Grand, JG; Hamaide, AJ; Le Couls, G; Snaps, FR; Verstegen, JP, 2006
)
0.78
" In conclusion, 2ME, alone or in combination with TRAIL, may be an effective treatment for cancers of uterine origin with minimal toxicity to corresponding healthy female reproductive tissue."( The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.
Brañes, J; Brosens, JJ; Cuello, M; Kato, S; Lange, S; Owen, GI; Sadarangani, A; Villalón, M, 2007
)
0.34
"To compare the efficacy of antimuscarinics alone versus antimuscarinics in combination with local oestrogens for OAB; to verify whether risk factors for lower antimuscarinic efficacy can be overcome by the concomitant use of local oestrogens."( Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
Bolis, P; Cardozo, L; Salvatore, S; Serati, M; Uccella, S, 2009
)
0.35
" Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1) with a random permuted block design to either daily oral estriol (8 mg) or placebo, each in combination with injectable glatiramer acetate 20 mg daily."( Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Arnold, DL; Bardens, J; Bernard, JT; Corboy, JR; Cross, AH; Dhib-Jalbut, S; Elashoff, R; Ford, CC; Frohman, EM; Giesser, B; Itoh, N; Jacobs, D; Kasper, LH; Kurth, F; Lynch, S; MacKenzie-Graham, AJ; Nakamura, K; Parry, G; Racke, MK; Reder, AT; Rose, J; Sicotte, NL; Tseng, CH; Voskuhl, RR; Wang, H; Wingerchuk, DM; Wu, TC, 2016
)
2.08

Bioavailability

ExcerptReferenceRelevance
" It is concluded that our knowledge of the intestinal and especially, the mucosal metabolism of steroids is scanty and further studies are needed to clarify the role of the intestine and enterohepatic circulation in determining the bioavailability of natural and synthetic steroids."( Steroid absorption and enterohepatic recycling.
Adlercreutz, H; Fotsis, T; Järvenpää, P; Martin, F, 1979
)
0.26
" Knowlege of bioavailability of natural and synthetic hormones in terms of their metabolism in the intestine and enterohepatic circulation is scanty."( Steroid absorption and enterohepatic recycling.
Adlercreutz, H; Fotsis, T; Järvenpää, P; Martin, F, 1979
)
0.26
" STS 593 differs from estradiol with respect to its higher bioavailability after oral administration; it amounts to 34-62% depending on the administration formulation."( [Pharmacokinetics of 14 beta-, 15 beta-methylenestratriene STS 593 after one-time and multiple administrations to beagles].
Hillesheim, HG; Schumann, W, 1987
)
0.27
"A bioavailability study was performed on ten oophorectomized women in a randomized cross-over design."( Bioavailability of oestradiol and oestriol administered orally to oophorectomized women.
Christensen, MS; Fink, BJ, 1981
)
0.54
" In particular, our objective was to examine whether one or both compounds were characterized by an improved oral bioavailability with less inter-subject variability than EE2."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" Specifically, they examined whether one or both of the new estrogens improved bioavailability with less inter-subject variability than EE2."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" The nasal and sublingual modes of administration rapidly convert estradiol into estrone, while the absorption rate through the cutaneous mode is even quicker, and subcutaneous implantation guarantees constant plasmatic levels for about 6 months."( [What happens in our patients' bodies to the steroid hormones we prescribe? Pt. 1. Estrogens].
Rozenbaum, H, 1981
)
0.26
" Thus, the bioavailability of 2-MeOE2 is very low, whereas for 2-MeOE2bisMATE it was 85%."( Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004
)
0.32
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The remediation of four estrogenic endocrine-disrupting compounds was measured in saturated and unsaturated carbonate sand-filled columns dosed with wastewater from a sewage treatment plant. When its effects are measured 24 h after a single injection, oestriol behaves as a typical impeded oestrogen with low potency and a flat dose-response line.

ExcerptRelevanceReference
" Dose-response curves of 3-day uterotrophic assays indicate that biological potency follows the order EE3CPE greater than EE3 or estradiol greater than E3CPE greater than E3."( Temporal relationships between hormone receptor binding and biological responses in the uterus: studies with short- and long-acting derivatives of estriol.
Katzenellenbogen, BS; Lan, NC, 1976
)
0.46
" The revised document should indicate the conditions under which various classes of substances constitute human health hazards -- including dosage levels and routes of entry."( Essential hormones as carcinogenic hazards.
Bowers, EJ; Clelland, RC; Hickey, RJ, 1979
)
0.26
" The results of the carcinogenic effects of these natural substances is in question because of administered dosage levels, chemical structure of the substances, the route the hormones entered the biological system, and testing done in animals and in vitro."( Essential hormones as carcinogenic hazards.
Bowers, EJ; Clelland, RC; Hickey, RJ, 1979
)
0.26
" It is likely that a higher dosage would be more effective, but would cause the potential endometrial effects."( Bone loss during oestriol therapy in postmenopausal women.
Clark, AC; Garwood, J; Hart, DM; Kraszewski, A; Lindsay, R; Maclean, A, 1979
)
0.59
" Its concentration in the blood is sensitive to endogenous or exogenous estrogens in a dose-response manner and serves as a biological assay for estrogens."( Corticosteroid-binding globulin and estrogens in maternal and cord blood.
Finn, AE; Jawad, MJ; Rayburn, W; Wilson, EA, 1979
)
0.26
" Clinical effectiveness was directly related to dosage (2 to 8 mg/day)."( Estriol in the management of the menopause.
Aksu, MF; Greenblatt, RB; Tzingounis, VA, 1978
)
1.7
" Each patient received one substance over 5 days doubling the dose every consecutive day, and switching to another estrogen after a treatment free interval of 2 days, rising the dosage of the second preparation twofold every consecutive day over another 5 days."( [Comparative high rising dose study of oral 17-alpha-ethinylestradiol (EE2), estriol (E3), and parenteral 16-alpha-17-beta-estrioldihemisuccinate (E3-suc) in their effects on serum levels of glutamate transaminase (GOT), pyruvate transaminase (GPT), leuci
Kohler, P; Leis, D; Zach, H, 1978
)
0.49
" Each of 3 preparations (estriol (E), 17 alpha-ethinyl estradiol (17AEE), and estriol dihemisucconate (ED)) was administered for 5 days of 3 consecutive weeks, with the dosage of the preparation being doubled daily."( [Comparative high rising dose study of oral 17-alpha-ethinylestradiol (EE2), estriol (E3), and parenteral 16-alpha-17-beta-estrioldihemisuccinate (E3-suc) in their effects on serum levels of glutamate transaminase (GOT), pyruvate transaminase (GPT), leuci
Kohler, P; Leis, D; Zach, H, 1978
)
0.79
" With the second divided dosage the serum oestriol levels remained uniform."( Serum oestriol, oestrone and oestradiol concentrations during oral oestriol succinate treatment in ovariectomized women.
Grönroos, M; Kaihola, HL; Punnonen, R; Rauramo, L, 1978
)
0.98
" All compounds were active anti-implantational agents, varying in required dosage from 4 mug to 2000 mug (total dosage over 4 days)."( Post-coital contraceptive activity and estrogen receptor binding affinity of phenolic steroids.
Müller, RE; Wotiz, HH, 1977
)
0.26
" point out the meaning of the urinary estriol dosage in high risk pregnancy."( [Rate meaning of estriol-dosage in the pregnant wife pointing out the phoetus development (author's transl)].
Candi, L; Cappiello, R; Davi, D; Vallini, A; Vernotico, V; Zanella, B, 1976
)
0.87
" When its effects are measured 24 h after a single injection, oestriol behaves as a typical impeded oestrogen with low potency and a flat dose-response line."( Oestriol, oestradiol-17beta and the proliferation and death of uterine cells.
Fagg, B; Martin, L; Pollard, JW, 1976
)
1.41
" These results confirm the dose-response relation previously established with plasma oestrogen measurements alone."( The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992
)
0.28
" The depot form allows for decreased dosing frequency, leading to improved compliance."( [Effectiveness of estriol depot vaginal suppositories in postmenopausal women with urogenital climacteric manifestations].
Beck, B; Benz, J; Köchli, OR; Schär, G, 1992
)
0.62
" 15 women (Group I) received 1 mg oestriol applied daily intravaginally over 3 weeks; 15 women (Group II) received a daily dosage of 3 mg and 10 women received a placebo."( [The effectiveness of intravaginal estriol tablet administration in women with urge incontinence].
Enzelsberger, H; Huber, J; Kurz, C; Schatten, C, 1991
)
0.84
" The data fitted log dose-response curves."( The effect of oestriol and tamoxifen on oestradiol induced prolactin secretion in anaesthetised rats.
Gilna, P; Martin, F, 1986
)
0.62
"The dose-response effects on serum lipids and lipoproteins were studied in 87 healthy post-menopausal women treated for 1 yr with three different doses of sequential oestrogen/progestogen (4 mg, 2 mg and 1 mg 17 beta-oestradiol cyclically combined with 1 mg norethisterone acetate) or placebo."( Dose-response effects on serum lipids and lipoproteins following combined oestrogen-progestogen therapy in post-menopausal women.
Christiansen, C; Jensen, J, 1987
)
0.27
" Applications range from ocular inserts to transdermal patches to oral dosage forms."( Membrane systems: practical applications.
Smith, KL, 1985
)
0.27
" The results showed reduced levels of both estrogens in smokers as compared with nonsmokers in all three dosage groups."( Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause.
Christiansen, C; Jensen, J; Rødbro, P, 1985
)
0.27
" 5 patients participated in a dose-response tolerance study in which the drug was given over a 12-hour period at predetermined dose levels from 25-200 mcg/minute."( Hormone levels during prostaglandin F 2 infusions for therapeutic abortion.
Anderson, GG; Brock, WA; Caldwell, BV; Hobbins, JC; Speroff, L, 1972
)
0.25
" All 3 tissues produced progesterone in a significant dose-response relationship with added pregnenolone but chorion was significantly more active than the other membranes."( Local modulation of progesterone production in human fetal membranes.
Challis, J; Cruickshank, B; McLean, D; Mitchell, B, 1982
)
0.26
" These results show that a low intravenous dosage of betamethason and collection of blood samples for E3 assays in intervals of 12 hours can be used as a functional test of the fetoplacental unit."( [The betamethasone test in the diagnosis of placental insufficiency].
Bernaschek, G; Bieglmayer, C; Friedrich, F, 1983
)
0.27
" Forty-two climacteric women were studied before and after treatment with various drugs at different doses (patients receiving identical compounds served as their own controls for the evaluation of dosage effects; duration of medication: 14 days at each dose)."( Effects of various replacement oestrogens on hepatic transcortin synthesis in climacteric women.
Hammerstein, J; Moltz, L; Schneller, E; Schwartz, U; Volger, H, 1983
)
0.27
" Also, there was much individual variation in dose-response of serum oestrogens to plasma renin substrate concentrations."( Plasma renin substrate and oestrogens in normal pregnancy.
Fyhrquist, F; Immonen, I; Kärkkäinen, J; Siimes, A; Stenman, UH, 1983
)
0.27
" These results suggest that the method and dosage of PGE2 used in this study do not affect hormonal regulations in the maternal-fetoplacental unit and that we may use hormonal levels as an indicator of fetal well-being even during PGE2 administration."( [The influences of prostaglandin E2 on hormones in maternal-fetoplacental unit].
Azegami, M; Lee, CH; Miyakawa, I; Mori, N; Taniyama, K, 1984
)
0.27
" Low concentrations of E3 (10(-10) M) stimulate growth of MCF-7 cells in vitro and dose-response curves show E3 to be only slightly less effective than E2."( Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo.
Katzenellenbogen, BS, 1984
)
0.54
" The dosages of E3 employed appear to vary considerably, and the need was felt to establish the dosage on a scientific basis."( The significance of oestriol in the management of the post-menopause.
Aksu, MF; Greenblatt, RB; Tzingounis, VA, 1980
)
0.58
" Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively."( Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture.
Bayard, F; Jozan, S; Kreitmann, B, 1981
)
0.54
" The oestrogen preparations available, the dosage schemes, and the modes of administration are the main aspects of therapy which will be discussed in this paper."( Oestrogen therapy in the peri-menopause: A practical approach.
Haspels, AA, 1980
)
0.26
" Suppression of cortisol and estrogens was greater after dexamethasone (Dx) than after a glucocorticoid-equivalent dosage of prednisone (Pd)."( Loss of diurnal rhythm in plasma estrone, estradiol, and estriol in women treated with synthetic glucocorticoids at 34 to 35 weeks' gestation.
Challis, J; Patrick, J; Richardson, B; Tevaarwerk, G, 1981
)
0.51
" Although a lower dosage of estriol may be recommended for elderly subjects, these observations suggest that hormone replacement therapy with estriol is effective against degenerative osteoporosis, and that low-turnover bones in elderly women are also responsive to estriol."( [Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women].
Fukuo, K; Hirota, K; Ikegami, H; Morimoto, S; Nishibe, A; Ogihara, T; Onishi, T; Yamamoto, T; Yasuda, O, 1996
)
0.98
" They received continuously 17 beta estradiol in dosage 2 mg daily and 1 mg of norethisterone acetate daily during one year period."( [Effect of Kliogest therapy on serum blood lipids in postmenopausal women].
Dydowicz, M; Hadaś, K; Halerz-Nowakowska, B; Korcz-Maciejewska, M; Meczekalski, B; Warenik-Szymankiewicz, A; Wiza, M, 1995
)
0.29
" This study demonstrates that, in the red-eared slider, there is a complex interaction between incubation temperature, different estrogens, and the dosage effect of each hormone."( The relative effectiveness of estrone, estradiol-17 beta, and estriol in sex reversal in the red-eared slider (Trachemys scripta), a turtle with temperature-dependent sex determination.
Cantú, AR; Crews, D; Rhen, T; Vohra, R, 1996
)
0.53
" The dosage included single intravenous (60 mcg) and oral (120 and 240 mcg) administration."( Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann, A; Brudny-Klöppel, M; Bunte, T; Draeger, C; Fuhrmeister, A; Kuhnz, W, 1996
)
0.29
" Incubating spleen cells from untreated mice in concentrations of 16-epiestriol ranging from 1 mg/ml to 100 pg/ml did not alter profiles of IFN-gamma production, in contrast to the suppressive dose-response effects of hydrocortisone."( 16-Epiestriol, a novel anti-inflammatory nonglycogenic steroid, does not inhibit IFN-gamma production by murine splenocytes.
Allen, D; Bates, R; Bjorndahl, J; Bouma, C; Burgio, D; Latman, N; Miller, E; Stoll, J, 1998
)
1.01
"A fluorimetric liquid chromatographic method (lambda(ex) = 280 nm; lambda(em) = 312 nm) was developed for measurements of unconjugated estrogens (estradiol and estriol) in pharmaceutical dosage forms using a reversed-phase column with water acetonitrile at different composition as mobile phase."( HPLC-fluorescence determination of unconjugated estrogens in pharmaceuticals.
Cavrini, V; Di Pietra, AM; Gatti, R; Gioia, MG, 1998
)
0.5
" Data from assays measuring increases in uterine wet weight in rats were evaluated in terms of their dose-response characteristics."( Dose-response characteristics of uterine responses in rats exposed to estrogen agonists.
Allen, BC; Andersen, ME; Barton, HA, 1998
)
0.3
" These variations depend on the different methods of dosage and on individual variations among patients."( [What happens in our patients' bodies to the steroid hormones we prescribe? Pt. 1. Estrogens].
Rozenbaum, H, 1981
)
0.26
" The D-ring metabolites did not show such clear biphasic patterns, in most of them the stimulatory effect prevailed at the highest dosage used."( The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells.
Lippert, C; Mueck, AO; Seeger, H, 2003
)
0.32
" Blood samples were taken from the jugular vein before treatment, frequently on days 1, 3 and 7 of the treatment period and daily just before (C(trough)) and 1 h after dosing (C(t=1h))."( Pharmacokinetics of oestriol after repeated oral administration to dogs.
Coert, A; Hoeijmakers, M; Horspool, L; Janszen, B, 2003
)
0.64
" A preliminary dose-response study performed in weanling rats determined 2000 microg/kg/day to be the optimal dose of 16alpha-OHE(1) for studying estrogenic effect on bone."( Comparative effects of long-term continuous release of 16 alpha-hydroxyestrone and 17 beta-estradiol on bone, uterus, and serum cholesterol in ovariectomized adult rats.
Kennedy, AM; Lotinun, S; Turner, RT; Westerlind, KC, 2003
)
0.32
"The dosage and time of evaluation for study arm 1 was not ideal for providing documented increases in hormone levels."( Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina.
Glaser, RL; Wurtzbacher, D; Zava, DT, 2008
)
0.35
" Dose-response patterns were frequently nonmonotonic."( Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation.
Jeng, YJ; Kochukov, MY; Watson, CS, 2008
)
0.59
"03 mg estriol resulted in a very low systemic bioavailability, which decreased even more after multiple dosing confirming a favourable safety profile of low dose pessaries administered daily over 21 days."( Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries.
Borregaard, S; Buhling, KJ; Eydeler, U; Schlegelmilch, R; Suesskind, M, 2012
)
1.15
" The role of the compounding pharmacist was vital to achieve appropriate dosing of a drug no longer commercially available."( Medical therapy for acquired urinary incontinence in dogs.
Griffin, K; Hill, K; Jordan, D; Mays, AA; Ray, J,
)
0.13
"Bioidentical compounded hormone therapy is popular among patients, but providers do not have pharmacokinetic information or dosing guidelines for these preparations."( Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial.
Bahn, RS; Rhodes, DJ; Schroeder, DR; Shuster, LT; Singh, RJ; Sood, R; Wahner-Roedler, D; Warndahl, RA, 2013
)
0.39
" Effects of initial pH and CaO2 dosage were investigated."( Performance of calcium peroxide for removal of endocrine-disrupting compounds in waste activated sludge and promotion of sludge solubilization.
Li, Y; Wang, J; Zhang, A, 2015
)
0.42
"The remediation of four estrogenic endocrine-disrupting compounds (EDCs), estrone (E1), estradiol (E2), ethinylestradiol (EE2) and estriol (E3), was measured in saturated and unsaturated carbonate sand-filled columns dosed with wastewater from a sewage treatment plant."( Behaviour of estrogenic endocrine-disrupting chemicals in permeable carbonate sands.
Erler, DV; Eyre, BD; Kimber, S; Shepherd, BO; Tait, DR; van Zwieten, L, 2015
)
0.62
" Modeling results suggest that for E1, E2 and EE2, AOB-linked biodegradation is dominant over biodegradation by HB at all investigated COD dosing levels."( Model-based assessment of estrogen removal by nitrifying activated sludge.
Dai, X; Liu, Y; Ni, BJ; Peng, L; Song, S; Sun, J, 2018
)
0.48
" Pharmacokinetic parameters after repeated dosing of vaginal pessaries showed a dose-dependent, but not dose-proportional, increase of plasma progesterone levels."( Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo.
Duijkers, IJM; Hrafnsdottir, S; Klingmann, I; Klipping, C; Magnusdottir, TB; Prinz, R; Wargenau, M, 2018
)
0.48
" No significant difference was observed between various dosages and dosage forms of vaginal estrogen products."( A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.
Biehl, C; Mirkin, S; Plotsker, O, 2019
)
0.51
" In this concise paper, we evaluate the use a roller mill in the final steps of compounding semisolid dosage forms."( Towards the Importance of a Roller Mill in Compounding Practice: An Experimental Approach.
Batista, PF; Brandão, MAF; da Silva, SL; de, OFA; Polonini, H,
)
0.13
" In this article, we present a simple method to analyze the dose-response curve of a mixture and to determine an agonistic bioanalytical equivalent concentration: a concentration of a reference chemical that would elicit the same effect as do only agonists in an unknown mixture."( The agonistic bioanalytical equivalent concentration: A novel tool for assessing the endocrine activity of environmental mixtures.
Ezechiáš, M, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
estrogenA hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
16alpha-hydroxy steroidA 16-hydroxy steroid in which the hydroxy group at position 16 has alpha-configuration.
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Estrone Metabolism1622
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Biochemical pathways: part I0466

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency9.14230.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency14.79930.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency3.95610.000657.913322,387.1992AID1259377; AID1259378; AID1259394
progesterone receptorHomo sapiens (human)Potency32.53680.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency25.44040.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency10.53460.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.34650.000229.305416,493.5996AID1259244; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency64.86010.000323.4451159.6830AID743065; AID743067
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.63790.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.63790.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.00170.00000.723732.7000AID625258
Estrogen receptorHomo sapiens (human)Ki0.00050.00000.42297.9070AID625258
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)39.34500.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki17.88400.00010.38637.0010AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)39.34500.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki17.88400.00070.76537.0010AID625263
Corticosteroid-binding globulinHomo sapiens (human)Ki10.00000.01323.248110.0000AID51055
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)8.63500.11003.26419.0330AID625146
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)436.51600.00101.979414.1600AID255211
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)39.34500.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki17.88400.00070.78467.0010AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)39.34500.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki17.88400.00070.78467.0010AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)39.34500.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki17.88400.00070.78467.0010AID625263
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)10.33600.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki5.49100.00000.70488.1930AID625222
Alpha-synucleinHomo sapiens (human)IC50 (µMol)20.10000.19003.82049.8000AID1695728
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Ki9.80001.10004.51259.8000AID681147
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.23440.00020.34964.7863AID318680
Lanosterol 14-alpha demethylaseMycobacterium tuberculosis H37RvKd100.00000.20000.42001.3000AID351876
Olfactory receptor 51E2Homo sapiens (human)EC50 (µMol)53.00000.00000.07800.5700AID1639697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A10Homo sapiens (human)Km68.40002.74004.21005.6800AID1222858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (207)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processCorticosteroid-binding globulinHomo sapiens (human)
negative regulation of endopeptidase activityCorticosteroid-binding globulinHomo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
androgen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B7Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
cell migrationOlfactory receptor 51E2Homo sapiens (human)
melanocyte differentiationOlfactory receptor 51E2Homo sapiens (human)
steroid hormone mediated signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
positive regulation of blood pressureOlfactory receptor 51E2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of smellOlfactory receptor 51E2Homo sapiens (human)
cellular response to fatty acidOlfactory receptor 51E2Homo sapiens (human)
melanocyte proliferationOlfactory receptor 51E2Homo sapiens (human)
positive regulation of renin secretion into blood streamOlfactory receptor 51E2Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A10Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (86)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingCorticosteroid-binding globulinHomo sapiens (human)
serine-type endopeptidase inhibitor activityCorticosteroid-binding globulinHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 2B7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B7Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
nuclear steroid receptor activityOlfactory receptor 51E2Homo sapiens (human)
G protein-coupled receptor activityOlfactory receptor 51E2Homo sapiens (human)
olfactory receptor activityOlfactory receptor 51E2Homo sapiens (human)
signaling receptor activityOlfactory receptor 51E2Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein kinase C bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (54)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
extracellular regionCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular exosomeCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
early endosome membraneOlfactory receptor 51E2Homo sapiens (human)
intracellular organelleOlfactory receptor 51E2Homo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (123)

Assay IDTitleYearJournalArticle
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID186982Affinity constant was measured by inhibition of estrus in ovariectomized rats treated with 17-beta-estradiol1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Antiestrogenic properties of substituted benz[a]anthracene-3,9-diols.
AID1222825Drug metabolism in human liver microsomes assessed as estriol-16-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1222859Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A4-mediated estriol-16-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID69706Relative Binding affinity was determined against estrogen receptor of lamb uterine cytosol at 0 degree Celsius relative to estradiol1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
11 beta-substituted estradiol derivatives. 2. Potential carbon-11- and iodine-labeled probes for the estrogen receptor.
AID1222858Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A10-mediated estriol-3-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID68899Estrogen receptor (ER) binding affinity1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1222857Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B4-mediated estriol-16-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID681147TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing HeLa cells1996The American journal of physiology, Feb, Volume: 270, Issue:2 Pt 2
Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1222824Drug metabolism in human liver microsomes assessed as estriol-3-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID1695728Inhibition of alpha-synuclein aggregation (unknown origin) incubated for 8 days by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID212920Binding affinity against transport protein testosterone binding globulin.1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1222861Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B7-mediated estriol-16-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID212931Binding affinity towards human testosterone binding globulin.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID1222833Drug metabolism in human intestine microsomes assessed as estriol-17-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID69841Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
11 beta-Substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity relationship study.
AID1222865Drug metabolism assessed as human UGT1A10 F93G mutant-mediated estriol-3-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID1222832Drug metabolism in human intestine microsomes assessed as estriol-16-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID212919Binding affinity towards testosterone binding globulin is expressed as log(1/k).1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID681612TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells2004Pharmaceutical research, Jul, Volume: 21, Issue:7
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
AID51056Binding affinity to the corticosteroid-binding globulin (CBG) receptor.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID351876Binding affinity to Mycobacterium tuberculosis His4-tagged recombinant CYP51 substrate binding site expressed in Escherichia coli HMS174(DE3) by UV-visible spectral titration method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID1222856Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2A1-mediated estriol-16-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1222863Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A8-mediated estriol-3-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID51055Binding affinity to human CBG receptor (corticosteroid-binding globulins)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
AID197231Oral estrogenic activity in uterotropic assay in rats at 1000-40000 ng dose1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and biological activity of some 15-oxaestranes.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID69834Relative Binding affinity was determined against estrogen receptor of lamb uterine cytosol at 25 degree Celsius relative to estradiol1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
11 beta-substituted estradiol derivatives. 2. Potential carbon-11- and iodine-labeled probes for the estrogen receptor.
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID681136TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells1999Molecular pharmacology, Apr, Volume: 55, Issue:4
Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID103554Growth response in cultures of MCF-7 (human breast cancer cell line) cells1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
AID55149The compound was tested in vitro for its ability to initiate DNA replication1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Effect of steroids on DNA synthesis in an in vitro replication system: initial quantitative structure-activity relationship studies and construction of a non-estrogen receptor pharmacophore.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID69840Relative binding affinity was measured on estrogen receptor of lamb uterine cytosol.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
11 beta-Substituted estradiol derivatives, potential high-affinity carbon-11-labeled probes for the estrogen receptor: a structure-affinity relationship study.
AID51059Binding affinity to corticosteroid binding globulin1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID1222862Drug metabolism assessed as recombinant human C-terminal His-tagged UGT1A1-mediated estriol-3-glucuronide formation at 200 uM after 15 to 60 mins by HPLC analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1222831Drug metabolism in human intestine microsomes assessed as estriol-3-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID1222864Drug metabolism assessed as recombinant human C-terminal His-tagged UGT2B17-mediated estriol-17-glucuronide formation after 15 to 60 mins by Michaelis-Menten equation analysis in presence of UDPGA2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID51058Binding affinity towards corticosteroid-binding globulin (CBG)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID55148The compound was tested in vitro for its ability to initiate DNA replication1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Effect of steroids on DNA synthesis in an in vitro replication system: initial quantitative structure-activity relationship studies and construction of a non-estrogen receptor pharmacophore.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,916)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904343 (73.41)18.7374
1990's609 (10.29)18.2507
2000's474 (8.01)29.6817
2010's397 (6.71)24.3611
2020's93 (1.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.99 (24.57)
Research Supply Index8.79 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index172.50 (26.88)
Search Engine Supply Index3.39 (0.95)

This Compound (56.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials309 (4.95%)5.53%
Reviews330 (5.29%)6.00%
Case Studies189 (3.03%)4.05%
Observational4 (0.06%)0.25%
Other5,411 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]